

1 **Increased adverse events following third dose of BNT162b2/Pfizer vaccine in**  
2 **those with previous COVID-19, but not with concurrent influenza vaccine.**

3

4 Rachael K. Raw (PhD)<sup>1\*</sup>, Jon Rees (MBBS)<sup>2</sup> and David R. Chadwick (PhD)<sup>3</sup>

5 <sup>1</sup> School of Medicine and Health, Newcastle University, Newcastle upon Tyne, UK

6 <sup>2</sup>The School of Psychology, University of Sunderland, UK

7 <sup>3</sup>Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, UK

8

9 **\* Corresponding author**

10 **Rachael Kathleen Raw**

11 **Email:** [Rachael.raw3@nhs.net](mailto:Rachael.raw3@nhs.net)

12 **Telephone:** +447780652723

13 **Manuscript type:** Article

14 **Key Words:** SARS-CoV-2; COVID-19; COVID-19 Vaccination; Vaccine-Associated  
15 Adverse Events; Long-COVID; Vaccine Hesitancy; Influenza; Influenza Vaccination.

16 **Number of words:** 2082

17 **Number of references:** 20

18 **Number of figures:** 2

19 **Number of tables:** 2

20

21

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 **Abstract**

23 Prior studies suggest that adverse events (AEs) following doses one and two of  
24 BNT162b2/Pfizer vaccine are worse in those with a prior history of COVID-19. To establish  
25 whether this outcome applies to a third/booster dose, we conducted a survey with 534  
26 healthcare workers (HCW) in Northeast England, who reported AEs following all three doses  
27 of BNT162b2/Pfizer vaccine. We also explored AEs associated with concurrent seasonal  
28 influenza immunisation. For all doses of BNT162b2/Pfizer vaccine there was a cluster of  
29 systemic AEs that were consistently worse in HCWs with a prior history of COVID-19. AEs  
30 were no worse in HCWs who received their third/booster dose within 7 days of the influenza  
31 jab, rather than further apart. Gender and the presence of ongoing COVID-19 symptoms  
32 (OCS) had no effect on AEs associated with COVID-19 or influenza vaccination, though  
33 younger HCWs experienced more AEs overall. Our findings have implications for vaccine  
34 hesitancy and immunisation protocols.

35

36

## 37 **1. Introduction**

38 Global vaccination efforts against SARS-CoV-2 began in late 2020, with BNT162b2/Pfizer<sup>[1]</sup>,  
39 mRNA-1273/Moderna<sup>[2]</sup>, and ChAdOx1/AstraZeneca<sup>[3]</sup> vaccines applied predominantly in the  
40 UK population. Healthcare Workers (HCWs) have been a priority target group. Phase three  
41 trials demonstrated general safety of these vaccines, but adverse events (AEs) have been  
42 widely reported, albeit mostly mild-to-moderate in nature and short in duration<sup>[4-10]</sup>. We have  
43 previously demonstrated an association between prior COVID-19 infection and increased AEs  
44 following administration of dose one of BNT162b2/Pfizer vaccine, but not after dose two<sup>[9,10]</sup>.  
45 The presence of "ongoing COVID-19 symptoms" (OCS; symptoms persisting from 4-12  
46 weeks)<sup>[11]</sup> was also associated with increased AEs after the second dose of BNT162b2/Pfizer  
47 vaccine<sup>[9,10]</sup>.

48

49 In late 2021, a 'booster' dose of COVID-19 vaccine was recommended, and as of May 2022,  
50 just under 40 million UK citizens had received this third dose<sup>[12]</sup>. To our knowledge, it is  
51 unknown whether the previously observed effects of factors such as COVID-19 history carry  
52 over to the booster dose. Furthermore, due to the timing of booster vaccinations, many eligible  
53 individuals, particularly HCWs, were invited to receive their COVID-19 booster at the same  
54 time as their seasonal influenza jab, which raises the question of whether concomitant  
55 influenza/COVID-19 vaccination may enhance AEs. Large trials have shown that co-  
56 administration of influenza vaccine with the second dose of a COVID-19 vaccination (including  
57 NVX-CoV2373<sup>[13]</sup>, ChAdOx1<sup>[14]</sup> or BNT162b2<sup>[14]</sup>) did not yield any worse AEs than when the  
58 COVID-19 vaccine was delivered on its own. No study has yet looked at concomitant  
59 administration in the context of the COVID-19 third/booster dose.

60

61 The primary aim of our present study was to explore the impact of risk factors for vaccine-  
62 associated AEs following the third/booster dose of BNT162b2/Pfizer vaccine in HCWs. This  
63 included prior COVID-19 history, the presence of OCS, and HCWs' age/gender. We also  
64 examined whether prior COVID-19 history would lead to worse AEs following the influenza

65 jab. As a secondary aim, in a small subgroup, we also compared AEs between those who  
66 received their BNT162b2/Pfizer booster around the time of their Influenza jab, and HCWs who  
67 had their vaccinations > 7 days apart.

68

## 69 **2. Method**

70 HCWs recruited from three Northeast England hospitals, formed an opportunistic sample.  
71 HCWs were invited via email to complete an online survey, which captured their experience  
72 of AEs following first, second and third/booster doses of the BNT162b2/Pfizer vaccine. AEs  
73 were documented using a modified version of the FDA Toxicity Grading Scale.<sup>[15]</sup> as previously  
74 described<sup>[9,10]</sup>. HCWs indicated whether they had received influenza vaccine within 7 days of  
75 the COVID-19 booster dose. If HCWs did not receive both vaccinations within this time  
76 interval, they were also asked to describe AEs following the influenza vaccine. Prior COVID-  
77 19 history was classed as positive for HCWs with self-reported positive PCR and/or COVID-  
78 19 test(s). All participants gave their written informed consent, and Cambridge East Research  
79 Ethics Committee approved this study, which was performed in accordance with the ethical  
80 standards laid down in the 1964 Declaration of Helsinki.

81

82 The number of moderate-to-severe AEs persisting >24hr were calculated for doses one, two  
83 and three of BNT162b2/Pfizer, and for influenza where it was not administered concomitantly.  
84 For BNT162b2/Pfizer doses one and two, AEs were only counted as moderate/severe if they  
85 were rated as “similar or worse than my current symptoms”. Effects of age, gender, presence  
86 of OCS, and whether influenza vaccine was administered concomitantly were also considered.

87

88 Statistical analysis was conducted using JASPV0.16.3.0. Frequencies of categorical variables  
89 and the occurrence of any moderate-to-severe AEs were examined using the chi-square test.  
90 Scores were compared using 2-way ANOVA and ANCOVA where age and gender were  
91 relevant. Multivariable logistic regressions were applied to identify the relationship between

92 COVID-19 status and moderate-to-severe AEs, and the Bonferroni correction applied to the  
93 resulting significance/confidence intervals. Correlation/tests of difference explored  
94 associations between AEs and age/gender.

95

### 96 **3. Results**

97 Five-hundred and thirty-four HCWs responded to the questionnaires (15% male, mean age  
98 49.6yr [SD-10.6]. Looking at prior COVID-19 history, 147/454 (32.3%) self-reported previous  
99 COVID-19. 492 (92.1%) had received influenza vaccine: 56 HCWs (11.4%) had it within 7  
100 days of their third BNT162b2/Pfizer dose, 292 HCWs (59.4%) had their doses >7 days apart.  
101 144 HCWs (29.3%) did not indicate time interval.

102

103 Initial analyses revealed a significant negative relationship between age and the number of  
104 moderate-to-severe AEs following third BNT162b2/Pfizer and influenza vaccines  
105 (BNT162b2/Pfizer Kendall's-tau=-0.16; influenza Kendall's-tau=-0.14;both p<0.001).  
106 However, for BNT162b2/Pfizer there was no significant relationship between age and number  
107 of AEs reported following doses one and two. There was a significant strong positive  
108 relationship between number of AEs reported for doses one and two (Kendall's-  
109 tau=0.46;p<0.001), a negative relationship between AEs following doses one and three  
110 (Kendall's-tau=-0.13;p<0.001), but no relationship between number of AEs for doses two or  
111 three, or between each of doses two and three, and the number of influenza AEs reported.  
112 There were no significant differences in number of AEs reported by male versus female  
113 HCWs, as shown in Table 1.

114

115 - Insert Table 1 –

116

117 For occurrence of one or more moderate/severe AEs, there was a significant association with  
118 previous COVID-19 and BNT162b2/Pfizer dose one (O.R.-1.64[1.13–2.38];p=0.011), dose  
119 two (O.R.-1.63[1.12–2.35];p=0.011), dose three (O.R.-2.44[1.67–3.55];p<0.001), and  
120 between previous history of COVID-19 and occurrence of AEs following the influenza vaccine  
121 (O.R.-1.88[1.25–2.82];p=0.002). To investigate the effect of prior COVID-19 on number of AEs  
122 following all three BNT162b2/Pfizer vaccines, a two-by-three (AEs x vaccine dose) ANOVA  
123 was performed. Age and gender were not used as covariates here given the non-significance  
124 of relationships identified with doses one and two, as described above. There was an overall  
125 main effect of prior COVID-19 ( $F(1.8, 957.7)=48.63;p<0.001$ ), whereby HCWs with prior  
126 COVID-19 reported 2.59 [2.39–2.79] versus 1.91[1.71–2.12] AEs (Figure 1A). There was a  
127 significant difference in number of AEs reported following dose one ( $F(1,527)=19.93;p<0.001$ ),  
128 with post-hoc testing (Bonferroni-p<0.05) demonstrating that the number of AEs reported for  
129 dose three (1.36 [1.14–1.59]) was significantly lower than reported for dose one (2.84[2.61–  
130 3.07]), and dose two (2.55[2.32–2.78]). There was no interaction between vaccine dose and  
131 COVID-19 history (Figure 1A).

132

133 To investigate the difference in number of AEs between BNT162b2/Pfizer dose three and the  
134 influenza vaccine, together with the role of interval between each vaccine, a two-by-two-way  
135 ANCOVA (vaccine x dosage interval), with age and gender as covariates (given the significant  
136 relationships here with dose three), was performed. Overall, there were significantly more AEs  
137 following BNT162b2/Pfizer dose three (1.28[1.07–1.49]), compared to the influenza vaccine  
138 (0.81[0.60–1.02]; Figure 1B); AEs  $F(1,331)=3.86;d=0.28[0.19–0.37];p<0.001$ , but there was  
139 no significant effect of interval between vaccines ( $F(1,331)=0.02;p=0.88$ ), and no interaction  
140 between these variables ( $F(1,311)=0.61;p=0.44$ ; Figure 1C).

141

142 - Insert Figure 1 –

143

144 Given the association between occurrence of any influenza AEs and prior COVID-19, we  
145 investigated this further. A two-by-two-way ANCOVA (vaccine-type x prior COVID-19) was  
146 performed, with age and gender as covariates. The overall significant difference in number of  
147 AEs between prior COVID-19 and influenza was maintained ( $F(1,470)=1.06;p<0.001$ ), but  
148 there was also a significant overall effect of prior COVID-19 with those previously symptomatic  
149 reporting more AEs across both types of vaccine ( $F(1,470)=11.73;p<0.001$ ), but crucially a  
150 significant interaction between vaccine type and COVID-19 history  $F(1,470)=4.16;p=0.04$ ). A  
151 simple effects analysis revealed this interaction was due to significantly larger numbers of AEs  
152 to BNT162b2/Pfizer vaccine in those with prior COVID-19 ( $t(527)=3.61,p<0.001;d=0.34[0.15-$   
153  $0.52]$ ), whilst the difference in number of AEs following influenza vaccine was not significant  
154 ( $t(488)=1.78;p=0.08;d=0.17[-0.02-0.36]$ ).

155

156 A similar pattern of results was found for prolonged AEs, which were scored as total number  
157 of vaccine-associated AEs rated as moderate/severe, lasting >24 hours. In this instance, an  
158 ANCOVA found significantly higher numbers of prolonged AEs associated with  
159 BNT162b2/Pfizer vaccine compared to influenza ( $1.09[0.96-1.23]$  v  $0.32[0.19-0.45]$ ; AEs  
160  $F(1,511)=15.24;p<0.001$ ), a higher number of prolonged AEs in those with prior COVID-19,  
161 than without ( $0.84[0.69-1.00]$  v  $0.57[0.42-0.72]$ ; AEs ( $F(1,511)=4.09;p=0.044$ ), and a  
162 significant interaction between these variables ( $F(1,511)=7.13;p=0.008$ ). A simple effects  
163 analysis showed that the number of prolonged moderate-to-severe AEs was again only  
164 significantly higher following BNT162b2/Pfizer vaccine ( $t(528)=3.03;d=0.28[0.10-$   
165  $0.47];p=0.003$ ), with no significant difference in prolonged AEs for the influenza vaccine  
166 ( $t(532)=0.44;d=0.04[-0.14-0.22];p=0.66$ ).

167

168 Incidence of each type of AE following BNT162b2/Pfizer dose three for those with and without  
169 prior COVID-19, is shown in Table 2. As in our previous work, the cluster of headache, fatigue,  
170 myalgia and arthralgia were most common in HCWs with prior COVID-19. Overall, the  
171 incidence of AEs to dose three were remarkably like those following the first two doses.  
172 Looking at the types of AEs most frequently reported, headache, fatigue, and myalgia were  
173 associated with prior COVID-19 for the third/booster dose of BNT162b2/Pfizer, after correcting  
174 for multiple comparisons, age and gender (Figure 2; Table 2). The effect for arthralgia was  
175 very nearly significant ( $p=0.06$ ). A similar analysis for time interval between influenza and  
176 BNT162b2/Pfizer dose three, found no significant relationship for occurrence of any of the  
177 vaccine-associated AEs (all  $p>0.9$ ).

178

179 - Insert Table 2 and Figure 2 –

180

181 Comparing the subset of HCWs with OCS ( $n=32$ ), with those without OCS, there was a similar  
182 reduction in number of AEs to BNT162b2/Pfizer dose three, compared to doses one and two  
183 ( $F(1.82,957.8)=11.89;p<0.001$ ; dose one 2.91[2.41–3.4]; dose two 2.48[1.97–2.98]; dose  
184 three 1.44[1.08–1.80]; Bonferroni-corrected post-hoc for dose three being significantly  
185 different [ $p<0.05$ ] to doses one and two. There was no significant overall difference in number  
186 of AEs between groups ( $F(1,527)=0.03;p=0.86$  (OCS mean 2.30[1.73–2.87]; control mean  
187 2.25[2.10–2.39]), and no significant interaction ( $F(1.82, 957.8)=0.15;p=0.84$ ). This suggests  
188 that OCS had no effect on number of AEs reported at each BNT162b2/Pfizer dose interval.  
189 Furthermore, there was no significant difference in number of AEs experienced following the  
190 influenza jab, between those with versus without OCS (without= $0.70$ ;SD-1.5; with= $0.56$ ,SD-  
191 1.4; AEs  $d=0.09[-0.30–0.56];p=0.54$ ).

192



193

194

#### 195 **4. Discussion**

196 Our previous work highlighted risk factors for increased BNT162b2/Pfizer vaccine-associated  
197 AEs, specifically females, younger age, prior COVID-19, and OCS were associated with  
198 increased AEs reported following doses one and/or two<sup>[9,10]</sup>. The main findings of our present  
199 study were firstly, that frequency of AEs to BNT162b2/Pfizer vaccination progressively  
200 reduced across all doses. Nevertheless, moderate-to-severe AEs were markedly more  
201 common in our cohort compared to the COV-BOOST trial that used the same AE grading  
202 system following third/booster doses of BNT162b2/Pfizer (AEs<5%;n=96)<sup>[16]</sup>. Our finding of  
203 progressive reductions in AEs across successive doses contrasts with both our prior work  
204 (showing AEs increased between doses one and two<sup>[10]</sup>) and a recent Israeli stud showing the  
205 opposite effect<sup>[17]</sup>. This might have occurred because either the present work involved a new  
206 sample of HCWs (hence individual differences) or HCWs becoming more accustomed to  
207 vaccine-associated AEs over time. Similarly, another surprising result was that gender did not  
208 appear to influence AEs, whereas our past studies have consistently shown females to report  
209 more AEs following doses one and two of BNT162b2/Pfizer vaccination<sup>[9,10]</sup>. Younger  
210 participants in the present study reported more AEs following the third/booster  
211 BNT162b2/Pfizer dose, and the influenza vaccine, the former finding being consistent with our  
212 and other's prior work<sup>[9,10,20]</sup>.

213

214 Our second key finding was that the effect of prior COVID-19 on vaccine-associated AEs, was  
215 again carried over to the third/booster BNT162b2/Pfizer dose in terms of increased AEs.  
216 Nevertheless, the presence of self-reported OCS did not seem to impact AEs to  
217 BNT162b2/Pfizer vaccination at any of the dosage timepoints, although our sample of HCWs  
218 with OCS was notably small.

219

220 Regarding the effect of influenza vaccination on AEs experienced around the time of the  
221 third/booster BNT162b2/Pfizer dose, our analysis was somewhat limited by the small number  
222 of HCWs that received their influenza vaccine within 7 days of t BNT162b2/Pfizer vaccination  
223 (n=56). Analyses did however show that HCWs in this subgroup reported similar  
224 numbers/levels of AEs compared to individuals who received vaccines more than 7 days apart.  
225 This supports previous safety data, which found no worse AEs reported following concomitant  
226 administration of influenza with doses one or two of COVID-19 vaccines<sup>[13,14]</sup>.

227

228 Limitations of the present work include the large sample imbalance for participant gender (85%  
229 female), and the retrospective recall (up to 12 months) of AEs in the present study. Given that  
230 vaccine safety plays a central role in people's decision to accept a vaccination, our present  
231 work has implications for vaccine hesitancy<sup>[18-20]</sup>. We found that BNT162b2/Pfizer-related AEs  
232 diminished with each successive dose and were no worse than the AEs reported by HCWs  
233 following influenza vaccine, which has been widely accepted for many years. Our present work  
234 also provides preliminary data to support concomitant administration of the third/booster  
235 BNT162b2/Pfizer vaccination alongside the influenza vaccine.

236

## 237 **5. Conclusion**

238 Prior history of COVID-19 was associated with increased AEs to both BNT162b2/Pfizer  
239 vaccination (at all three dosage points). The presence of OCS and female gender had no  
240 impact on AEs to BNT162b2/Pfizer or influenza vaccination, though younger HCWs  
241 experienced more AEs. Lastly, AEs were no worse in HCWs who received concomitant  
242 booster BNT162b2/Pfizer and influenza vaccines.

243

244

245 **Contributors**

246 DRC/JR/RKR conceived the study and DRC is chief investigator of CHOIS. RKR acted as site  
247 principal investigator. DRC/RKR/CW contributed to the study protocol, design, and data  
248 collection. JR did the statistical analysis. RKR/JR/DRC prepared the manuscript. All authors  
249 critically reviewed and approved the final version.

250

251 **Funding Sources**

252 The CHOIS study was supported by the North East and North Cumbria Academic Health  
253 Sciences Network (AHSN).

254

255 **Conflict of Interest**

256 No conflicts of interest.

257

258 **Acknowledgements**

259 We would like to thank the CHOIS research team, John Rouse and the North East and North  
260 Cumbria NIHR for assistance with the survey.

261

262 **Data Availability**

263 All data will be made available upon request.

264

265 **References**

- 266 1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA  
267 Covid-19 Vaccine. *N Engl J Med* 2020; 28: 2603-3615. doi:  
268 <https://doi.org/10.1056/NEJMoa2034577>.
- 269 2. Baden LER, El Sahly HM, Essink B et al. Efficacy and Safety of the mRNA-1273 SARS-  
270 CoV-2 Vaccine. *N Engl J Med*. 2021; 384 (5): 403-416. doi:  
271 <https://doi.org/10.1056/NEJMoa2035389>.
- 272 3. Voysey M, Clemens SAC, Madhi SA et al. Safety and efficacy of the ChAdOx1 nCoV-  
273 19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised  
274 controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397(10269):99-111.  
275 doi: [https://doi.org/10.1016/S0140-6736\(20\)32661-1](https://doi.org/10.1016/S0140-6736(20)32661-1).
- 276 4. Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA  
277 COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported  
278 symptoms from healthcare workers. *Int J Infect Dis*. 2021;106:376-381. doi:  
279 <https://doi.org/10.1016/j.ijid.2021.04.047>.
- 280 5. Krammer F, Srivastava K, Alshammary H et al. Antibody Responses in Seropositive  
281 Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med*.  
282 2021;384(14):1372-1374. doi: <https://doi.org/10.1056/NEJMc2101667>.
- 283 6. Tré-Hardy M, Cupaiolo R, Papeux E et al. Reactogenicity, safety and antibody  
284 response, after one and two doses of mRNA-1273 in seronegative and seropositive  
285 healthcare workers. *J Infect*. 2021; 83(2):237–79. doi:  
286 <https://doi.org/10.1016/j.jinf.2021.03.025>.
- 287 7. Ebinger JE, Fert-Bober J, Printsev I et al. Antibody responses to the BNT162b2 mRNA  
288 vaccine in individuals previously infected with SARS-CoV-2. *Nat Med*. 2021;27(6):981-  
289 984. doi: <https://doi.org/10.1038/s41591-021-01325-6>.
- 290 8. Mathioudakis AG, Ghrew M, Ustianowski A et al. Self-Reported Real-World Safety and  
291 Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. *Life (Basel)*.  
292 2021;11(3):249. <https://doi.org/10.3390/life11030249>.

- 293 9. Raw RK, Kelly CA, Rees J, Wroe C, Chadwick DR. Previous COVID-19 infection, but  
294 not Long-COVID, is associated with increased adverse events following  
295 BNT162b2/Pfizer vaccination. *J Infect.* 2021:S0163-4453(21)00277-2. doi:  
296 <https://doi.org/10.1016/j.jinf.2021.05.035>.
- 297 10. Raw RK, Rees J, Kelly CA, Wroe C, Chadwick DR. Prior COVID-19 infection is  
298 associated with increased Adverse Events (AEs) after the first, but not the second,  
299 dose of the BNT162b2/Pfizer vaccine. *Vaccine.* 2022; 40(3):418-423. doi:  
300 <https://doi.org/10.1016/j.vaccine.2021.11.090>.
- 301 11. National Institute of Clinic Excellence (NICE), Scottish Intercollegiate Guidelines  
302 Network (SIGN), Royal College of General Practitioners (RCGP). 2021. COVID-19  
303 rapid guideline: managing the long-term effects of COVID-19.  
304 <https://www.guidelines.co.uk/infection/nice-long-covid-guideline/455728.article>  
305 (accessed 25 July 2022).
- 306 12. United Kingdom Government. Coronavirus (COVID-19) in the UK: Vaccinations in  
307 United Kingdom., 2022. <https://coronavirus.data.gov.uk/details/vaccinations>  
308 (accessed 25 July 2022).
- 309 13. Toback S, Galiza E, Cosgrove C et al. CoV-302 Study Group. Safety, immunogenicity,  
310 and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal  
311 influenza vaccines: an exploratory substudy of a randomised, observer-blinded,  
312 placebo-controlled, phase 3 trial. *Lancet Respir Med.* 2022;10(2):167-179. doi:  
313 [https://doi.org/10.1016/S2213-2600\(21\)00409-4](https://doi.org/10.1016/S2213-2600(21)00409-4).
- 314 14. Lazarus R, Baos S, Cappel-Porter H et al. Safety and immunogenicity of concomitant  
315 administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal  
316 influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised,  
317 controlled, phase 4 trial. *Lancet.* 2021;398(10318):2277-2287. doi:  
318 [https://doi.org/10.1016/S0140-6736\(21\)02329-1](https://doi.org/10.1016/S0140-6736(21)02329-1).

- 319 15. Food and Drug Administration. Guidance for Industry Toxicity Grading Scale for  
320 Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical  
321 Trials. 2021. <https://www.fda.gov/media/73679/download> (accessed July 25, 2022).
- 322 16. Munro APS, Janani L, Cornelius V et al. Safety and immunogenicity of seven COVID-  
323 19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or  
324 BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled,  
325 phase 2 trial. *Lancet*. 2021; 398: 2258–76. doi: [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)02717-3)  
326 [6736\(21\)02717-3](https://doi.org/10.1016/S0140-6736(21)02717-3).
- 327 17. Merav Mofaz, Matan Yechezkel, Grace Guan et al. Self-Reported and Physiologic  
328 Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose. *Emerg Infect*  
329 *Dis*. 2022. 28(7): 1375-1383. doi: <https://doi.org/10.3201/eid2807.212330>.
- 330 18. Freeman D, Loe BS, Chadwick A et al. COVID-19 vaccine hesitancy in the UK: the  
331 Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. *Psychol*  
332 *Med*. 2020:1-15. doi: <https://doi.org/10.1017/S0033291720005188>.
- 333 19. Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. *Nat*  
334 *Med*. 2021. doi: <https://doi.org/10.1038/s41591-021-01459-7>.
- 335 20. Robertson E, Reeve KS, Niedzwiedz CL et al. Predictors of COVID-19 vaccine  
336 hesitancy in the UK household longitudinal study. *Brain Behav Immun*. 2021;94:41-50.  
337 doi: <https://doi.org/10.1016/j.bbi.2021.03.008>.

338


339

340

341

342


343 **Figures and Captions**



356 **Figure 1. Frequency of AEs by Vaccine Type, Prior COVID-19 Status and Interval**  
 357 **Between Doses. A.** Number of AEs according to previous COVID-19 history, for all three  
 358 BNT162b2/Pfizer doses. **B.** Number of AEs according to previous COVID-19 history for  
 359 BNT162b2/Pfizer third/booster dose and the seasonal influenza vaccine. **C.** Number of AEs  
 360 according associated with the influenza vaccine versus BNT162b2/Pfizer third/booster dose  
 361 for those HCWs who had these vaccines  $\leq$  or  $>$  7 days apart.

362

363



364  
 365 **Figure 2. Moderate and Severe AEs by COVID-19 Status:** Percentage of cases reporting  
 366 moderate or severe AEs (95% CI) following BNT162b2/Pfizer third/booster dose in those with  
 367 and without a history of COVID-19. N & V: nausea and vomiting.

368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376



377 **Tables and Captions**

378

	<b>Male (n=80)</b>	<b>Female (n=454)</b>	p	d [95% C.I.]
Age	48.7 (11.5)	49.6 (10.7)	-	-
BNT162b2/Pfizer Dose 1	2.84 (2.85)	2.86 (2.75)	0.95	0.008 [-0.23 – 0.25]
BNT162b2/Pfizer Dose 2	2.44 (2.90)	2.55 (2.80)	0.74	0.04 [-0.2 – 0.28]
BNT162b2/Pfizer Dose 3	0.99 (1.97)	1.43 (2.01)	0.07	0.22 [-0.02 – 0.46]
Influenza	0.78 (1.79)	0.76 (1.48)	0.90	- 0.02 [-0.26 – 0.23]

379 **Table 1. Number of AEs by Participant Gender and Vaccine Dose:** Mean (S.D) number  
380 of AEs reported by male versus female HCWs for all three BNT162b2/Pfizer doses and the  
381 seasonal Influenza vaccine.

382

383

384

385

386

387

388

389

390

---

	<b><u>Dose 3</u></b>	
	<b>Odds Ratio</b>	<b><i>p</i></b>
	<b>(95% C.I.)</b>	
<b>Fever</b>	1.44 (0.55 3.81)	>.99
<b>Fatigue</b>	2.37 (1.32 4.27)	<.001
<b>Myalgia</b>	2.25 (1.18 4.28)	0.001
<b>Arthralgia</b>	2.10 (0.98 4.46)	0.06
<b>Lymphadenopathy</b>	0.79 (0.79 1.40)	>.99
<b>Local Pain</b>	1.43 (0.77 2.65)	>.99
<b>Local Redness</b>	2.56 (0.77 8.53)	0.33
<b>Local Swelling</b>	3.15 (0.82 12.11)	0.18
<b>Nausia &amp; Vomiting</b>	0.51 (0.12 2.12)	>.99
<b>Diarrhoea</b>	1.49 (0.23 9.47)	>.99
<b>Headache</b>	2.03 (1.10 3.77)	0.011

---

391 **Table 2. Moderate and Severe AEs by COVID-19 Status:** Percentage of cases reporting  
392 moderate or severe AEs following BNT162b2/Pfizer third/booster dose (95% CI) in those with  
393 and without a history of COVID-19 (the former including OSC).

394

395